Howard R. Levin

CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way.

Coridea NC1, Inc. provides treatment for diastolic heart failure, refractory angina and end-stage renal diseases. The company was founded in 2010 by Howard R. Levin and Mark Gelfand and is headquartered in New York, NY.

Cibiem, Inc. operates as a medical device company. Its catheter-based approach focuses on carotid body modulation for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure. The company was founded by Mark Gelfand and Howard R. Levin and is headquartered in Los Altos, CA.

Ardian, Inc. manufactures the symplicity catheter systems. It is a medical device company that develops and researches catheter-based treatment for diseases such as hypertension, chronic kidney diseases, metabolic syndrome and heart failure. The company was founded by Denise Demarais Zarins, Allan R. Will, Henry A. Plain Jr., Howard R. Levin and Mark Gelfand in 2003 and is headquartered in Mountain View, CA.

Evalve, Inc. designs, develops, manufactures and markets devices. It developed a proprietary system which enables percutaneous repair of cardiac valves. The firm's products reduces the risks, trauma, and costs associated with current open, arrested heart surgical options. The company was founded on June 9, 1999 and is headquartered in Menlo Park, CA.

Respicardia, Inc. is a holding company, which engages in the provision of cardiovascular ultra-sound diagnostic devices. The company was founded by Theodore C. Skokos, Mark Gelfand, Dr. Howard R. Levin and Dr. Danny Sachs in 2006 and is headquartered in Minnetonka, MN.

Part of VNS Choice, New York-Presbyterian Health System Select LLC is a hospital operator. The company is based in New York, NY.

Coridea LLC develops and manufactures medical devices. The firm provides treatment for diastolic heart failure, refractory angina and end-stage renal diseases. The company was founded by Mark Gelfland and Howard R. Levin in 2003 and is headquartered in New York, NY.